CDC4 Antibody

What is CDC4/FBXW7 and why is it significant in research?

CDC4 (Cell Division Control protein 4), also known as FBXW7, is a critical F-box protein that functions within the SCF (Skp1-Cul1-F-box) ubiquitin ligase complex. It plays essential roles in cell cycle regulation by targeting specific proteins for ubiquitination and subsequent proteasomal degradation. The significance of CDC4/FBXW7 extends to multiple phases of the cell cycle, particularly during G1/S and G2/M transitions . Mutations in CDC4 have been linked to various cancers, including ovarian and breast cancer, making CDC4 antibodies vital tools for investigating cell cycle dysregulation in tumorigenesis .

How do CDC4 antibodies differ across species reactivity?

CDC4 antibodies demonstrate variable cross-reactivity across species based on epitope conservation. Available CDC4 antibodies show reactivity patterns that differ significantly between mammals and other vertebrates. For instance, human FBXW7/CDC4 antibodies typically detect the protein at approximately 110 kDa in human cell lines like Jurkat (acute T cell leukemia) . When selecting an antibody for cross-species applications, researchers should verify sequence homology at the epitope region and conduct validation tests using positive controls from the target species. The selection process should prioritize antibodies raised against conserved regions if multi-species applications are planned.

What are the fundamental applications for CDC4 antibodies in research?

CDC4 antibodies have been validated for multiple research applications including:

• Western Blot (WB): Detecting CDC4/FBXW7 protein levels and post-translational modifications in cell and tissue lysates

• Immunoprecipitation (IP): Isolating CDC4 and its binding partners for interaction studies

• Immunocytochemistry/Immunofluorescence (ICC/IF): Visualizing subcellular localization and distribution patterns of CDC4

• Enzyme-Linked Immunosorbent Assay (ELISA): Quantitative measurement of CDC4 levels

These applications have been successfully employed in various experimental systems including human cell lines (HeLa, THP-1, Jurkat), mouse tissue homogenates, and PBMCs (peripheral blood mononuclear cells) .

What is the appropriate storage and handling protocol for CDC4 antibodies?

Proper storage and handling of CDC4 antibodies significantly impact their performance and longevity. Based on manufacturer recommendations:

• Long-term storage: Maintain at -20°C to -70°C for up to 12 months from receipt date

• Short-term storage: Store at 2-8°C under sterile conditions for up to 1 month after reconstitution

• Working aliquots: Store at -20°C to -70°C for up to 6 months under sterile conditions after reconstitution

• Avoid repeated freeze-thaw cycles by preparing single-use aliquots upon initial thawing

This storage protocol applies specifically to the Human FBXW7/CDC4 Antibody (MAB7776) but represents standard practice for most monoclonal antibodies targeting CDC4.

How can researchers distinguish between different isoforms of CDC4/FBXW7 using antibodies?

CDC4/FBXW7 exists in multiple isoforms (α, β, γ) with distinct subcellular localizations and potentially different functions. When designing experiments to distinguish between these isoforms:

• Select antibodies raised against isoform-specific regions; most commercial antibodies target common regions and will detect multiple isoforms

• Combine immunoblotting with high-resolution SDS-PAGE to separate isoforms based on molecular weight differences

• Employ isoform-specific siRNA knockdowns as controls to validate antibody specificity

• For immunofluorescence studies, co-stain with compartment-specific markers (nuclear, cytoplasmic, nucleolar) to correlate with known isoform localizations

When interpreting results, consider that the detection of a specific band at approximately 110 kDa typically represents the predominant isoform in most human cell types .

What methodological approaches resolve contradictory CDC4 antibody results?

When faced with contradictory results using CDC4 antibodies, researchers should implement a systematic troubleshooting approach:

• Validate antibody specificity through genetic approaches:

  • Compare results from wild-type and CDC4-knockout models

  • Use siRNA/shRNA-mediated knockdown of CDC4 as negative controls

  • Overexpress tagged versions of CDC4 as positive controls

• Employ multiple antibodies targeting different epitopes of CDC4

• Optimize experimental conditions specifically for each antibody:

  • Test different protein extraction methods (RIPA buffer vs. NP-40 vs. specialized extraction kits)

  • Modify blocking conditions (5% milk vs. BSA)

  • Adjust antibody concentration (reported optimal range: 2 μg/mL for Western blot applications)

• Consider context-dependent post-translational modifications that might affect epitope accessibility

Contradictory results often emerge from differences in experimental conditions rather than antibody quality, emphasizing the importance of methodological consistency.

How should CDC4 phosphorylation status be analyzed in relation to its function?

CDC4 function is intimately linked to its ability to recognize phosphorylated substrates through its WD40 domain. To analyze CDC4 phosphorylation:

• Use phospho-specific antibodies when available

• Employ phosphatase treatments as controls to confirm phosphorylation-dependent signals

• Implement Phos-tag SDS-PAGE to separate phosphorylated from non-phosphorylated CDC4 forms

• Combine immunoprecipitation with mass spectrometry to identify specific phosphorylation sites

Research has identified more than 70 phosphorylation sites on CCAN subunits, with several minimal Cdk1 sites detected on proteins like Ame1 (T31, S41, S45, S53) that interact with the CDC4 pathway . Understanding these phosphorylation patterns is essential for interpreting CDC4's role in targeting proteins for degradation.

What are the optimal conditions for Western blot detection of CDC4/FBXW7?

For optimal Western blot detection of CDC4/FBXW7, researchers should follow these methodological guidelines:

• Sample preparation:

  • Use reducing conditions when preparing cell lysates

  • Employ Immunoblot Buffer Group 1 for consistent results

  • Include protease and phosphatase inhibitors to prevent degradation

• Antibody concentrations and incubation:

  • Primary antibody (e.g., Mouse Anti-Human FBXW7/CDC4): Use at 2 μg/mL concentration

  • Secondary antibody (e.g., HRP-conjugated Anti-Mouse IgG): Dilute according to manufacturer recommendations

  • Perform primary antibody incubation overnight at 4°C for improved signal-to-noise ratio

• Detection membrane:

  • PVDF membrane provides better results than nitrocellulose for CDC4 detection

  • Pre-activation of PVDF with methanol is essential

• Expected results:

  • CDC4/FBXW7 typically appears as a specific band at approximately 110 kDa in human cell lines like Jurkat

Validation through positive controls (e.g., Jurkat cell lysates) and negative controls (CDC4 knockdown samples) is strongly recommended to ensure specificity.

How should researchers design experiments to study CDC4's role in cell cycle regulation?

When designing experiments to investigate CDC4's role in cell cycle regulation, consider these methodological approaches:

• Synchronization strategies:

  • Use hydroxyurea for S-phase arrest to study CDC4's function in G2/M transition

  • Apply alpha-factor arrest (in yeast) or serum starvation (in mammalian cells) for G1 synchronization

• Genetic manipulation approaches:

  • Generate temperature-sensitive CDC4 mutants (e.g., cdc4-12) that exhibit both G1/S and G2/M defects

  • Create CDC4 deletion strains (cdc4Δ) combined with SIC1 or PDS1 deletions to dissect specific cell cycle phase functions

• Cell cycle analysis methods:

  • Flow cytometry with propidium iodide staining for DNA content

  • EdU incorporation assays for S-phase analysis

  • Immunofluorescence for cell cycle markers (cyclins, CDKs)

• Substrate degradation monitoring:

  • Implement pulse-chase experiments with cycloheximide to measure substrate half-life

  • Use Western blotting with timed sample collection to track degradation of CDC4 targets

This experimental design has successfully revealed that CDC4 functions not only in G1/S transition but also plays a critical role in G2/M progression and anaphase initiation .

What approaches can identify novel CDC4 substrates in experimental systems?

To identify novel CDC4 substrates, researchers should implement a multi-faceted approach:

• Immunoprecipitation-based methods:

  • Use CDC4 antibodies conjugated to agarose beads for pulldown experiments

  • Perform tandem affinity purification with tagged CDC4 versions

• Proteomic screening strategies:

  • Compare global protein levels in CDC4 wild-type versus knockout/knockdown cells

  • Employ SILAC (Stable Isotope Labeling with Amino acids in Cell culture) to quantify protein turnover rates

• Bioinformatic prediction and validation:

  • Screen for proteins containing CDC4 phospho-degron motifs (CPDs)

  • Validate candidate interactions through co-immunoprecipitation and in vitro binding assays

• Functional validation:

  • Perform site-directed mutagenesis of predicted phospho-degron sites

  • Monitor protein stability using cycloheximide chase assays in CDC4-proficient versus CDC4-deficient backgrounds

Recent research has identified differential regulation of proteins like Ame1CENP-U through CDC4 phospho-degrons, demonstrating the value of these approaches in expanding our understanding of CDC4 substrate diversity .

How can researchers address non-specific binding issues with CDC4 antibodies?

Non-specific binding is a common challenge when working with CDC4 antibodies. To mitigate this issue:

• Optimize blocking conditions:

  • Test different blocking agents (5% non-fat milk, 3-5% BSA, commercial blocking buffers)

  • Extend blocking time to 2 hours at room temperature or overnight at 4°C

• Adjust antibody dilutions and incubation parameters:

  • Perform titration experiments to determine optimal antibody concentration

  • Consider reducing primary antibody concentration below the recommended 2 μg/mL if background persists

  • Increase washing duration and frequency (5 washes for 5 minutes each)

• Implement additional specificity controls:

  • Include lysates from CDC4 knockout or knockdown samples

  • Pre-absorb antibody with recombinant CDC4 protein

  • Use isotype control antibodies to identify Fc receptor-mediated binding

• Sample preparation considerations:

  • Ensure complete cell lysis while maintaining native protein structure

  • Remove cell debris through high-speed centrifugation

  • Consider pre-clearing lysates with Protein A/G beads before immunoprecipitation

These approaches have been successfully employed in studies using CDC4 antibodies for detection in complex samples like human tissue homogenates and cell lysates .

What methodological strategies help differentiate CDC4's cell cycle-specific functions?

To differentiate CDC4's functions across different cell cycle phases:

• Implement genetic separation-of-function approaches:

  • Study the G1/S function using cdc4Δ sic1Δ double mutants, which eliminates the G1/S block

  • Analyze G2/M function using cdc4Δ pds1Δ double mutants, which allows anaphase progression

• Utilize cell synchronization with phase-specific readouts:

  • Synchronize cells at specific cell cycle phases (G1, S, G2, M)

  • Release from synchronization and collect time-course samples

  • Monitor cell cycle markers and CDC4 substrates simultaneously

• Employ fluorescent reporters for real-time analysis:

  • Use fluorescently-tagged cell cycle regulators (cyclins, CDK inhibitors)

  • Implement live-cell imaging to track protein dynamics

• Design substrate-specific degradation assays:

  • Monitor Sic1 levels for G1/S transition function

  • Track Pds1 stability for G2/M and anaphase onset function

These approaches have revealed that CDC4 mutations can cause arrest both at G1/S and G2/M transitions, with different substrates being relevant at each phase .

How should researchers interpret differences in CDC4 antibody recognition patterns across tissue types?

When interpreting variations in CDC4 antibody recognition patterns across different tissue types:

• Consider tissue-specific expression of CDC4 isoforms:

  • α isoform predominates in nuclei of most cells

  • β isoform shows cytoplasmic localization

  • γ isoform exhibits nucleolar localization

• Account for tissue-specific post-translational modifications:

  • Phosphorylation status may vary by tissue type and affect epitope accessibility

  • Ubiquitination and other modifications could mask antibody binding sites

• Evaluate potential cross-reactivity with tissue-specific proteins:

  • Perform validation using multiple antibodies targeting different epitopes

  • Include appropriate tissue-specific negative controls

• Normalize data appropriately for cross-tissue comparisons:

  • Use multiple housekeeping proteins as loading controls

  • Consider tissue-specific extraction efficiency differences

Research has demonstrated variable CDC4 detection patterns across different cell lines, including Jurkat (T cell leukemia), HeLa, and THP-1 (monocytic leukemia) cells, highlighting the importance of cell type-specific validation .

What methodological approaches best characterize CDC4 mutations in cancer research?

For characterizing CDC4 mutations in cancer research contexts:

• Mutation identification and classification:

  • Implement targeted sequencing of CDC4/FBXW7 exons

  • Focus on hotspot regions in WD40 repeats (R465, R479, R505) commonly mutated in cancers

  • Classify mutations as missense, nonsense, or frameshift

• Functional characterization workflow:

  • Generate isogenic cell lines with wild-type or mutant CDC4 using CRISPR/Cas9

  • Assess substrate accumulation (c-Myc, cyclin E, Notch) in mutant versus wild-type backgrounds

  • Measure proliferation rates, cell cycle distribution, and genomic instability

• Patient sample analysis:

  • Use immunohistochemistry with validated CDC4 antibodies on tissue microarrays

  • Correlate CDC4 protein levels with mutation status and clinical outcomes

  • Analyze CDC4 substrate levels in patient-derived samples

• Therapeutic vulnerability screening:

  • Test CDC4-mutant cells for synthetic lethality with cell cycle checkpoint inhibitors

  • Evaluate sensitivity to proteasome inhibitors or specific E3 ligase modulators

These approaches have successfully linked CDC4 mutations to the development of ovarian and breast cancers, positioning CDC4 as both a biomarker and potential therapeutic target .

How can researchers accurately quantify CDC4-substrate interactions in experimental systems?

To quantify CDC4-substrate interactions accurately:

• In vitro binding assays:

  • Express and purify recombinant CDC4 and substrate proteins

  • Perform binding assays with varying substrate phosphorylation states

  • Use techniques like surface plasmon resonance (SPR) or microscale thermophoresis for quantitative binding constants

• Cellular interaction quantification:

  • Implement proximity ligation assays (PLA) to detect and quantify endogenous protein interactions

  • Use fluorescence resonance energy transfer (FRET) or bioluminescence resonance energy transfer (BRET) for live-cell interaction monitoring

  • Quantify co-immunoprecipitation efficiency through densitometry analysis

• Phosphorylation-dependent binding analysis:

  • Generate phosphomimetic and phospho-deficient substrate mutants

  • Compare binding affinity of wild-type versus mutant substrates

  • Use phospho-specific antibodies to correlate phosphorylation status with binding efficiency

• Substrate competition assays:

  • Test multiple substrates simultaneously to determine preferential binding

  • Implement in vitro ubiquitination assays to measure catalytic efficiency

These approaches have been instrumental in defining how CDC4 phospho-degrons allow differential regulation of proteins like Ame1CENP-U through recognition of specific phosphorylation patterns .